Ionis Pharmaceuticals, Inc. (IONS)
USD 25.98
(-4.1%)
USD 25.98
(-4.1%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -230.01 Million USD | 42.45% |
| 2022 | -227.75 Million USD | -2571.43% |
| 2021 | -239 Thousand USD | 87.79% |
| 2020 | -107.88 Million USD | -146.99% |
| 2019 | 411.53 Million USD | 694.6% |
| 2018 | -18.83 Million USD | -393.31% |
| 2017 | 39.79 Million USD | 145.31% |
| 2016 | -8.82 Million USD | 16.62% |
| 2015 | -40.93 Million USD | -99.62% |
| 2014 | -22.77 Million USD | 46.14% |
| 2013 | -37.42 Million USD | 0.59% |
| 2012 | -42.68 Million USD | 14.03% |
| 2011 | -56.27 Million USD | -58.94% |
| 2010 | -38.75 Million USD | -38.13% |
| 2009 | -9.79 Million USD | -421.75% |
| 2008 | 4.11 Million USD | 83.75% |
| 2007 | -26.15 Million USD | 49.44% |
| 2006 | -64.23 Million USD | -91.33% |
| 2005 | -42.4 Million USD | 13.4% |
| 2004 | -73.25 Million USD | 41.06% |
| 2003 | -64.92 Million USD | -34.5% |
| 2002 | -40.01 Million USD | -7.5% |
| 2001 | -39.13 Million USD | -712.96% |
| 2000 | -23.45 Million USD | 81.77% |
| 1999 | -37.9 Million USD | -12.87% |
| 1998 | -28.2 Million USD | 16.05% |
| 1997 | -28.1 Million USD | -5.54% |
| 1996 | -26.5 Million USD | -18.99% |
| 1995 | -22.8 Million USD | -7.05% |
| 1994 | -18.6 Million USD | -59.6% |
| 1993 | -15.1 Million USD | 30.41% |
| 1992 | -19.6 Million USD | -90.35% |
| 1991 | -9.6 Million USD | -134.15% |
| 1990 | -4.1 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -60.51 Million USD | 67.09% |
| 2024 Q1 | -143.86 Million USD | -556.76% |
| 2023 Q2 | -59 Million USD | 39.18% |
| 2023 Q4 | -1.67 Million USD | 98.64% |
| 2023 Q3 | -123 Million USD | -108.47% |
| 2023 Q1 | -97 Million USD | 72.91% |
| 2023 FY | - USD | 42.45% |
| 2022 Q4 | -358 Million USD | -606.32% |
| 2022 Q3 | -50.68 Million USD | 46.11% |
| 2022 Q1 | -53.74 Million USD | -124.32% |
| 2022 Q2 | -94.05 Million USD | -75.01% |
| 2022 FY | - USD | -2571.43% |
| 2021 Q3 | -80.61 Million USD | -42.06% |
| 2021 Q4 | 221 Million USD | 374.16% |
| 2021 Q1 | -83.92 Million USD | -264.9% |
| 2021 Q2 | -56.74 Million USD | 32.39% |
| 2021 FY | - USD | 87.79% |
| 2020 Q1 | -57.11 Million USD | -121.88% |
| 2020 Q2 | -47.87 Million USD | 16.18% |
| 2020 Q3 | -31.95 Million USD | 33.24% |
| 2020 FY | - USD | -146.99% |
| 2020 Q4 | -23 Million USD | 28.03% |
| 2019 Q3 | 6.06 Million USD | 131.92% |
| 2019 Q4 | 261 Million USD | 4204.09% |
| 2019 Q1 | 124.93 Million USD | 1062.69% |
| 2019 FY | - USD | 694.6% |
| 2019 Q2 | -19 Million USD | -115.21% |
| 2018 Q1 | -3.46 Million USD | -104.9% |
| 2018 Q3 | -15.34 Million USD | 67.56% |
| 2018 Q4 | 10.74 Million USD | 170.04% |
| 2018 Q2 | -47.28 Million USD | -1263.19% |
| 2018 FY | - USD | -393.31% |
| 2017 Q4 | -1.69 Million USD | -111.81% |
| 2017 Q2 | -1.67 Million USD | -111.2% |
| 2017 Q1 | 14.92 Million USD | -63.74% |
| 2017 FY | - USD | 145.31% |
| 2017 Q3 | 14.33 Million USD | 957.57% |
| 2016 Q3 | 18.38 Million USD | 139.4% |
| 2016 Q4 | 41.15 Million USD | 123.89% |
| 2016 FY | - USD | 16.62% |
| 2016 Q1 | -54.65 Million USD | 11.77% |
| 2016 Q2 | -46.65 Million USD | 14.63% |
| 2015 Q3 | -25.31 Million USD | -156.69% |
| 2015 FY | - USD | -99.62% |
| 2015 Q1 | -6.97 Million USD | -123.7% |
| 2015 Q4 | -61.94 Million USD | -144.72% |
| 2015 Q2 | 44.64 Million USD | 739.81% |
| 2014 FY | - USD | 46.14% |
| 2014 Q3 | -19.07 Million USD | -341.53% |
| 2014 Q4 | 29.44 Million USD | 254.38% |
| 2014 Q2 | -4.32 Million USD | 84.22% |
| 2014 Q1 | -27.37 Million USD | -37.84% |
| 2013 Q2 | -7.92 Million USD | -587.88% |
| 2013 Q1 | 1.62 Million USD | 120.24% |
| 2013 FY | - USD | 0.59% |
| 2013 Q4 | -19.85 Million USD | 22.14% |
| 2013 Q3 | -25.5 Million USD | -221.71% |
| 2012 Q2 | 4.01 Million USD | 121.29% |
| 2012 Q1 | -18.83 Million USD | 2.82% |
| 2012 Q3 | -27.63 Million USD | -789.23% |
| 2012 Q4 | -8.03 Million USD | 70.95% |
| 2012 FY | - USD | 14.03% |
| 2011 Q2 | -15.09 Million USD | 7.17% |
| 2011 Q3 | -22.7 Million USD | -50.41% |
| 2011 FY | - USD | -58.94% |
| 2011 Q4 | -19.37 Million USD | 14.65% |
| 2011 Q1 | -16.25 Million USD | -94.53% |
| 2010 Q1 | -6.36 Million USD | 45.45% |
| 2010 FY | - USD | -38.13% |
| 2010 Q2 | -22.61 Million USD | -255.23% |
| 2010 Q3 | -9.87 Million USD | 56.32% |
| 2010 Q4 | -8.35 Million USD | 15.38% |
| 2009 Q3 | -10.39 Million USD | -115.37% |
| 2009 FY | - USD | -421.75% |
| 2009 Q4 | -11.67 Million USD | -12.26% |
| 2009 Q2 | -4.82 Million USD | -651.87% |
| 2009 Q1 | -642 Thousand USD | -119.89% |
| 2008 Q2 | -4.88 Million USD | 64.54% |
| 2008 Q1 | -13.78 Million USD | -63.3% |
| 2008 FY | - USD | 83.75% |
| 2008 Q3 | -4.32 Million USD | 11.56% |
| 2008 Q4 | 3.22 Million USD | 174.65% |
| 2007 Q2 | -19.65 Million USD | 7.3% |
| 2007 Q4 | -8.44 Million USD | -183.95% |
| 2007 Q3 | 10.05 Million USD | 151.17% |
| 2007 Q1 | -21.2 Million USD | -62.39% |
| 2007 FY | - USD | 49.44% |
| 2006 FY | - USD | -91.33% |
| 2006 Q4 | -13.05 Million USD | 36.32% |
| 2006 Q3 | -20.5 Million USD | -3.58% |
| 2006 Q2 | -19.79 Million USD | -24.15% |
| 2006 Q1 | -15.94 Million USD | -116.54% |
| 2005 Q1 | -9.33 Million USD | -174.16% |
| 2005 Q3 | -14.08 Million USD | -21.16% |
| 2005 Q2 | -11.62 Million USD | -24.46% |
| 2005 FY | - USD | 13.4% |
| 2005 Q4 | -7.36 Million USD | 47.72% |
| 2004 Q3 | -17.88 Million USD | 16.19% |
| 2004 Q1 | -22.33 Million USD | 1.17% |
| 2004 FY | - USD | 41.06% |
| 2004 Q2 | -21.34 Million USD | 4.45% |
| 2004 Q4 | 12.59 Million USD | 170.41% |
| 2003 Q3 | -19.06 Million USD | -27.21% |
| 2003 Q4 | -21.48 Million USD | -11.64% |
| 2003 Q2 | -15.91 Million USD | 3.4% |
| 2003 Q1 | -18.91 Million USD | 2.88% |
| 2003 FY | - USD | -34.5% |
| 2002 FY | - USD | -7.5% |
| 2002 Q1 | -9.71 Million USD | -26.26% |
| 2002 Q3 | -17.5 Million USD | -123.84% |
| 2002 Q4 | -16.96 Million USD | 24.56% |
| 2002 Q2 | -12.33 Million USD | -3.36% |
| 2001 Q3 | -4.7 Million USD | 71.41% |
| 2001 FY | - USD | -712.96% |
| 2001 Q4 | -7.69 Million USD | -63.52% |
| 2001 Q2 | -16.46 Million USD | 4.47% |
| 2001 Q1 | -17.23 Million USD | -182.71% |
| 2000 Q3 | 206 Thousand USD | 224.32% |
| 2000 Q1 | -5.9 Million USD | 38.48% |
| 2000 Q2 | -3.58 Million USD | 39.37% |
| 2000 FY | - USD | 81.77% |
| 2000 Q4 | -6.09 Million USD | -236.93% |
| 1999 Q4 | -9.6 Million USD | -57.38% |
| 1999 Q3 | -6.1 Million USD | 40.78% |
| 1999 Q2 | -10.3 Million USD | 8.04% |
| 1999 FY | - USD | -12.87% |
| 1999 Q1 | -11.2 Million USD | -103.64% |
| 1998 Q2 | -14.2 Million USD | -17.36% |
| 1998 FY | - USD | 16.05% |
| 1998 Q4 | -5.5 Million USD | -450.0% |
| 1998 Q3 | -1 Million USD | 92.96% |
| 1998 Q1 | -12.1 Million USD | -2.54% |
| 1997 Q3 | -3.7 Million USD | 64.76% |
| 1997 FY | - USD | -5.54% |
| 1997 Q1 | -9.8 Million USD | 16.24% |
| 1997 Q2 | -10.5 Million USD | -7.14% |
| 1997 Q4 | -11.8 Million USD | -218.92% |
| 1996 FY | - USD | -18.99% |
| 1996 Q4 | -11.7 Million USD | -53.95% |
| 1996 Q3 | -7.6 Million USD | 16.48% |
| 1996 Q2 | -9.1 Million USD | -89.58% |
| 1996 Q1 | -4.8 Million USD | 35.14% |
| 1995 Q1 | -6.6 Million USD | 41.07% |
| 1995 Q4 | -7.4 Million USD | 9.76% |
| 1995 Q2 | -6.5 Million USD | 1.52% |
| 1995 Q3 | -8.2 Million USD | -26.15% |
| 1995 FY | - USD | -7.05% |
| 1994 FY | - USD | -59.6% |
| 1994 Q4 | -11.2 Million USD | -124.0% |
| 1994 Q2 | -4.8 Million USD | 37.66% |
| 1994 Q1 | -7.7 Million USD | -75.0% |
| 1994 Q3 | -5 Million USD | -4.17% |
| 1993 Q4 | -4.4 Million USD | 0.0% |
| 1993 FY | - USD | 30.41% |
| 1993 Q1 | -5.1 Million USD | 25.0% |
| 1993 Q2 | -4.6 Million USD | 9.8% |
| 1993 Q3 | -4.4 Million USD | 4.35% |
| 1992 Q4 | -6.8 Million USD | -58.14% |
| 1992 FY | - USD | -90.35% |
| 1992 Q2 | -3.7 Million USD | 21.28% |
| 1992 Q1 | -4.7 Million USD | 2.08% |
| 1992 Q3 | -4.3 Million USD | -16.22% |
| 1991 FY | - USD | -178.05% |
| 1991 Q3 | -2 Million USD | 16.67% |
| 1991 Q1 | -1.2 Million USD | 76.67% |
| 1991 Q2 | -2.1 Million USD | -71.43% |
| 1991 Q4 | -4.8 Million USD | -140.0% |
| 1990 Q2 | 500 Thousand USD | 0.0% |
| 1990 FY | - USD | 0.0% |
| 1990 Q1 | 500 Thousand USD | 0.0% |
| 1990 Q3 | 500 Thousand USD | 0.0% |
| 1990 Q4 | -6 Million USD | -1300.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AbCellera Biologics Inc. | -192.15 Million USD | -19.698% |
| Alkermes plc | 495.04 Million USD | 146.462% |
| Agenus Inc. | -145.92 Million USD | -57.623% |
| Aptorum Group Limited | -9.59 Million USD | -2296.188% |
| Ardelyx, Inc. | -55.35 Million USD | -315.526% |
| Dyadic International, Inc. | -8.22 Million USD | -2694.864% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | -78941.237% |
| Lantern Pharma Inc. | -15.78 Million USD | -1356.987% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | -1055.11% |
| Novavax, Inc. | -487.39 Million USD | 52.808% |
| Janux Therapeutics, Inc. | -71.02 Million USD | -223.848% |
| Pyxis Oncology, Inc. | -78.49 Million USD | -193.032% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | -1179.721% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | -2207.484% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | -300.882% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | 39.466% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | -853.927% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | 43580.151% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | -46.321% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | -207.439% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -1040.979% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | -869.075% |
| Clearside Biomedical, Inc. | -23.05 Million USD | -897.528% |
| C4 Therapeutics, Inc. | -122.1 Million USD | -88.374% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | 10.932% |
| AlloVir, Inc. | -190.14 Million USD | -20.965% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | -30.932% |
| VYNE Therapeutics Inc. | -29.25 Million USD | -686.144% |
| Bicycle Therapeutics plc | -183.4 Million USD | -25.414% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | -39.045% |
| ChromaDex Corporation | -3.89 Million USD | -5806.78% |
| Chimerix, Inc. | -92.97 Million USD | -147.392% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -417.613% |
| Caribou Biosciences, Inc. | -112.53 Million USD | -104.392% |
| CRISPR Therapeutics AG | -202.7 Million USD | -13.473% |
| Precision BioSciences, Inc. | -32.04 Million USD | -617.839% |
| Fate Therapeutics, Inc. | -172.22 Million USD | -33.549% |
| Fortress Biotech, Inc. | -133.64 Million USD | -72.108% |
| Fortress Biotech, Inc. | -133.64 Million USD | -72.108% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | -197.39% |
| ImmuCell Corporation | -2.5 Million USD | -9085.42% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | -76.36% |
| Immix Biopharma, Inc. | -16.13 Million USD | -1325.478% |
| Incyte Corporation | 919.42 Million USD | 125.017% |
| Innoviva, Inc. | 248.96 Million USD | 192.388% |
| IO Biotech, Inc. | -91.22 Million USD | -152.127% |
| Jaguar Health, Inc. | -33.13 Million USD | -594.244% |
| Keros Therapeutics, Inc. | -152.17 Million USD | -51.146% |
| Ligand Pharmaceuticals Incorporated | 101.72 Million USD | 326.105% |
| ContextLogic Inc. | -324 Million USD | 29.009% |
| MiMedx Group, Inc. | 40.51 Million USD | 667.688% |
| MEI Pharma, Inc. | 26.38 Million USD | 971.911% |
| NextCure, Inc. | -59.03 Million USD | -289.59% |
| Onconetix, Inc. | -36.7 Million USD | -526.615% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | 10391.275% |
| Opthea Limited | -200.01 Million USD | -14.994% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -8259.197% |
| Vaxcyte, Inc. | -464.88 Million USD | 50.523% |
| PDS Biotechnology Corporation | -40.08 Million USD | -473.806% |
| Precigen, Inc. | -89.22 Million USD | -157.784% |
| Pharming Group N.V. | 9.87 Million USD | 2428.744% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | -44.616% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | -910.5% |
| PureTech Health plc | -11.62 Million USD | -1878.24% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | -1254.514% |
| Avidity Biosciences, Inc. | -233.49 Million USD | 1.493% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | -853.927% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -163.088% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | -694.151% |
| Acelyrin, Inc. | -381.52 Million USD | 39.713% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | -1785014.192% |
| Summit Therapeutics Inc. | 1 Million USD | 23078.022% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | -588.941% |
| Senti Biosciences, Inc. | -61.33 Million USD | -275.0% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | -104.81% |
| Elevation Oncology, Inc. | -41.46 Million USD | -454.682% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | -644.273% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | -3660.456% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | -71554.206% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | -608.748% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | -2639.519% |
| Wave Life Sciences Ltd. | -58.79 Million USD | -291.24% |
| Seer, Inc. | -97.88 Million USD | -134.98% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | -269.809% |
| Aadi Bioscience, Inc. | -65.36 Million USD | -251.886% |
| ESSA Pharma Inc. | -26.45 Million USD | -769.429% |
| GlycoMimetics, Inc. | -39.12 Million USD | -487.93% |
| GT Biopharma, Inc. | 5.97 Million USD | 3946.964% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | -11.281% |
| Akebia Therapeutics, Inc. | -6.86 Million USD | -3249.01% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 364.952% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | -305.275% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | -349.072% |
| Alzamend Neuro, Inc. | -9.88 Million USD | -2226.411% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 57.4% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | -3241.226% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | -390.824% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | 2.794% |
| Aptose Biosciences Inc. | -52.26 Million USD | -340.059% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | -113.479% |
| Soligenix, Inc. | -7.85 Million USD | -2829.0% |
| Century Therapeutics, Inc. | -121.2 Million USD | -89.765% |
| Kura Oncology, Inc. | -164.95 Million USD | -39.438% |
| TScan Therapeutics, Inc. | -80.09 Million USD | -187.161% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | -2180.488% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | -23915.938% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | -5237.897% |
| Autolus Therapeutics plc | -156.77 Million USD | -46.718% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | -171.696% |
| EyePoint Pharmaceuticals, Inc. | -69 Million USD | -233.343% |
| Eterna Therapeutics Inc. | -19.93 Million USD | -1053.858% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | -21.523% |
| GRI Bio, Inc. | -10.89 Million USD | -2010.571% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -4993.546% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | -87.754% |
| IGM Biosciences, Inc. | -253.35 Million USD | 9.215% |
| INmune Bio, Inc. | - USD | Infinity% |
| Heron Therapeutics, Inc. | -103.79 Million USD | -121.607% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | -503.175% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | -1400.303% |
| Entero Therapeutics, Inc. | -15.74 Million USD | -1361.008% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | -304.627% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | -114.756% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 13.529% |
| Coherus BioSciences, Inc. | -193.93 Million USD | -18.599% |
| Verastem, Inc. | -83.16 Million USD | -176.567% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -354.817% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | -45.366% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | -101.606% |
| Histogen Inc. | -10.5 Million USD | -2089.946% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | -1510.747% |
| Surrozen, Inc. | -41.13 Million USD | -459.213% |
| Organovo Holdings, Inc. | -14.8 Million USD | -1453.492% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 7172223.48% |
| Ovid Therapeutics Inc. | -58.71 Million USD | -291.752% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | -348.415% |
| CASI Pharmaceuticals, Inc. | -21.53 Million USD | -967.877% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | -2658.574% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | -38.505% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | -366.945% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | -851.792% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | -1427.794% |
| Apollomics, Inc. | -171.74 Million USD | -33.924% |
| Amarin Corporation plc | -50.9 Million USD | -351.872% |
| Mesoblast Limited | -61.33 Million USD | -275.031% |
| Turnstone Biologics Corp. | -56.23 Million USD | -309.023% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | -60.62% |
| Synaptogenix, Inc. | -8.3 Million USD | -2668.701% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | -1399.511% |
| Aurinia Pharmaceuticals Inc. | -63.04 Million USD | -264.823% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -4700.41% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | 53710.511% |
| Exelixis, Inc. | 196.6 Million USD | 216.993% |
| Better Therapeutics, Inc. | -38.26 Million USD | -501.145% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | -62.656% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | 53.553% |
| NLS Pharmaceutics AG | -11.79 Million USD | -1849.955% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | 93140.094% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | -679.536% |
| Gritstone bio, Inc. | -126.86 Million USD | -81.306% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | -253.943% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | -5650.328% |
| Avid Bioservices, Inc. | -11.48 Million USD | -1903.397% |
| Insmed Incorporated | -654.73 Million USD | 64.87% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | -10123.944% |
| MediWound Ltd. | -4.89 Million USD | -4600.797% |
| OmniAb, Inc. | -49.73 Million USD | -362.508% |
| Alector, Inc. | -142.89 Million USD | -60.968% |
| Seres Therapeutics, Inc. | -85.43 Million USD | -169.225% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | -341.072% |
| Zai Lab Limited | -366.57 Million USD | 37.254% |
| Revance Therapeutics, Inc. | -290.63 Million USD | 20.86% |
| Aura Biosciences, Inc. | -83.69 Million USD | -174.816% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | -2.114% |
| Immunic, Inc. | -99.11 Million USD | -132.071% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | -74.687% |
| Veracyte, Inc. | -49.4 Million USD | -365.522% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | -3156.119% |
| FibroGen, Inc. | -261.4 Million USD | 12.01% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | -1964.536% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | -3185.234% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | -1128.892% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | 115.869% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | -804.768% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | 676.611% |
| TG Therapeutics, Inc. | 26.1 Million USD | 981.264% |
| Galecto, Inc. | -37.51 Million USD | -513.049% |
| Calithera Biosciences, Inc. | -38.26 Million USD | -501.098% |
| Fortrea Holdings Inc. | 167.3 Million USD | 237.484% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | -71.291% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | -712.44% |
| XBiotech Inc. | -35.76 Million USD | -543.097% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | -253.943% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | -252.506% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | -120.2% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | -795.957% |
| Theravance Biopharma, Inc. | -40.86 Million USD | -462.826% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | 55.464% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | -310.578% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -410258.424% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | -97.713% |
| Gain Therapeutics, Inc. | -22.16 Million USD | -937.504% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | 2.15% |
| NexImmune, Inc. | -28.16 Million USD | -716.579% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | -4062.664% |
| Marker Therapeutics, Inc. | -11.79 Million USD | -1850.515% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 104.942% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | -805.836% |
| Scopus BioPharma Inc. | -11.71 Million USD | -1863.691% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | -82.771% |
| Ainos, Inc. | -8.77 Million USD | -2521.765% |
| Pluri Inc. | -20.22 Million USD | -1037.256% |
| Prothena Corporation plc | -190.1 Million USD | -20.989% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | -79.418% |
| Celularity Inc. | -183.94 Million USD | -25.042% |
| Rallybio Corporation | -72.37 Million USD | -217.812% |
| Cue Biopharma, Inc. | -46.05 Million USD | -399.457% |
| MeiraGTx Holdings plc | -57.05 Million USD | -303.159% |
| Omeros Corporation | -163.61 Million USD | -40.584% |
| Humacyte, Inc. | -96.45 Million USD | -138.456% |
| Immunocore Holdings plc | -59.64 Million USD | -285.606% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | -1087.332% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | -844.018% |
| Blueprint Medicines Corporation | -474.61 Million USD | 51.537% |
| CalciMedica, Inc. | -34.18 Million USD | -572.76% |
| Cabaletta Bio, Inc. | -73.23 Million USD | -214.075% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | -83.279% |
| Scholar Rock Holding Corporation | -168.45 Million USD | -36.544% |
| Sana Biotechnology, Inc. | -252.39 Million USD | 8.867% |
| Pulmatrix, Inc. | -12.64 Million USD | -1718.836% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | -597.719% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | -159.995% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 54.572% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | -127.249% |
| Cytokinetics, Incorporated | -456.68 Million USD | 49.635% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | -589.21% |
| Nutriband Inc. | -5.12 Million USD | -4390.824% |
| Protara Therapeutics, Inc. | -43.27 Million USD | -431.545% |
| Vor Biopharma Inc. | -114.37 Million USD | -101.109% |
| Roivant Sciences Ltd. | -996.51 Million USD | 76.919% |
| Evogene Ltd. | -23.2 Million USD | -891.252% |
| ProKidney Corp. | -147.66 Million USD | -55.761% |
| Applied Therapeutics, Inc. | -64.53 Million USD | -256.411% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | -150087.073% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | 59.324% |
| CorMedix Inc. | -48.88 Million USD | -370.493% |
| BioLineRx Ltd. | -57.06 Million USD | -303.095% |
| Tango Therapeutics, Inc. | -111.75 Million USD | -105.811% |
| Galectin Therapeutics Inc. | -202 Thousand USD | -113766.337% |
| Atai Life Sciences N.V. | -36.31 Million USD | -533.444% |
| Renovaro Biosciences Inc. | -79.51 Million USD | -189.259% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | -182.87% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | 16.513% |
| Sagimet Biosciences Inc. | -30.74 Million USD | -648.243% |
| MediciNova, Inc. | -9.87 Million USD | -2228.044% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | -82.633% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -14931.359% |
| GeoVax Labs, Inc. | -26.66 Million USD | -762.469% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | -2.231% |
| Biomea Fusion, Inc. | -124.62 Million USD | -84.569% |
| PTC Therapeutics, Inc. | -330.34 Million USD | 30.372% |
| Mereo BioPharma Group plc | -26.05 Million USD | -782.753% |
| Cullinan Oncology, Inc. | -190.33 Million USD | -20.842% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | -0.03% |
| Absci Corporation | -95.45 Million USD | -140.957% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | -666.062% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | -114.726% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | 1.485% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | -906.388% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | -10.669% |
| Allakos Inc. | -189.91 Million USD | -21.112% |
| Imunon, Inc. | -19.87 Million USD | -1057.092% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | -112.006% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 312.335% |
| BioAtla, Inc. | -122.24 Million USD | -88.161% |
| NLS Pharmaceutics AG | -11.79 Million USD | -1849.955% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | -1359.362% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | 23.405% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | -454.95% |
| XOMA Corporation | -39.36 Million USD | -484.345% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | -131.739% |
| Cara Therapeutics, Inc. | -117.65 Million USD | -95.504% |
| aTyr Pharma, Inc. | -52.17 Million USD | -340.818% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | -174.426% |
| Akero Therapeutics, Inc. | -148.63 Million USD | -54.752% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 1.942% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | -1584.685% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | -2760.003% |
| Akari Therapeutics, Plc | -16.8 Million USD | -1268.944% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 121988.016% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 150.893% |
| Lexaria Bioscience Corp. | -6.38 Million USD | -3500.305% |
| UroGen Pharma Ltd. | -63.83 Million USD | -260.342% |
| Sutro Biopharma, Inc. | -67.91 Million USD | -238.673% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -3066.868% |
| Orgenesis Inc. | -60.71 Million USD | -278.817% |
| Entera Bio Ltd. | -8.8 Million USD | -2512.562% |
| GH Research PLC | -41.15 Million USD | -458.914% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | -801.328% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | -179.705% |
| Xencor, Inc. | -125.87 Million USD | -82.73% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | -16023.571% |
| Replimune Group, Inc. | -230.19 Million USD | 0.082% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | -1041.057% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | -2002.084% |
| Lexaria Bioscience Corp. | -6.38 Million USD | -3500.305% |
| Portage Biotech Inc. | -18.19 Million USD | -1163.861% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -14931.359% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | -119.928% |
| OncoCyte Corporation | -23.12 Million USD | -894.724% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | -1935.422% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | -1907.622% |
| Purple Biotech Ltd. | -22.22 Million USD | -934.916% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | -3488.3% |
| scPharmaceuticals Inc. | -46.06 Million USD | -399.36% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | -1191.489% |
| HilleVax, Inc. | -132.46 Million USD | -73.637% |
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | -2063.171% |
| Tharimmune, Inc. | -9.3 Million USD | -2372.537% |
| Genprex, Inc. | -31.06 Million USD | -640.521% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | -22.655% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | -633.591% |
| XTL Biopharmaceuticals Ltd. | -764 Thousand USD | -30006.021% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | 152521.407% |
| OKYO Pharma Limited | -15.74 Thousand USD | -1460663.997% |
| Savara Inc. | -59.13 Million USD | -288.971% |
| Curis, Inc. | -45.13 Million USD | -409.559% |
| Daré Bioscience, Inc. | -30.7 Million USD | -649.181% |
| Carmell Therapeutics Corporation | -15.19 Million USD | -1414.105% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | -3110.188% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | -760.365% |
| BeiGene, Ltd. | -1.12 Billion USD | 79.548% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | -1311.0% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | 46.582% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | -154.605% |
| Erasca, Inc. | -121.31 Million USD | -89.605% |
| bluebird bio, Inc. | -167.16 Million USD | -37.598% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | -5012.747% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 174.129% |
| DBV Technologies S.A. | -85.98 Million USD | -167.509% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | -5012.747% |
| Moderna, Inc. | -3.28 Billion USD | 92.994% |
| Vincerx Pharma, Inc. | -42.6 Million USD | -439.816% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | -3972.415% |
| Molecular Templates, Inc. | 1.43 Million USD | 16184.615% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | -284.298% |
| Travere Therapeutics, Inc. | -326.24 Million USD | 29.498% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | -67.782% |
| Spruce Biosciences, Inc. | -47.36 Million USD | -385.601% |
| Celldex Therapeutics, Inc. | -139.03 Million USD | -65.434% |
| Cogent Biosciences, Inc. | -205.86 Million USD | -11.731% |
| MacroGenics, Inc. | 2.01 Million USD | 11503.57% |
| RenovoRx, Inc. | -11.39 Million USD | -1919.403% |
| Adicet Bio, Inc. | -136.53 Million USD | -68.462% |
| Prime Medicine, Inc. | -193.75 Million USD | -18.709% |
| Aditxt, Inc. | -25.45 Million USD | -803.489% |
| Adagene Inc. | -14.95 Million USD | -1438.448% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -3046.469% |
| Quantum-Si incorporated | -91.8 Million USD | -150.545% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | 132.286% |
| Acurx Pharmaceuticals, Inc. | - USD | Infinity% |
| Voyager Therapeutics, Inc. | 126.45 Million USD | 281.891% |
| SciSparc Ltd. | -5.28 Million USD | -4254.601% |
| Vericel Corporation | 2.86 Million USD | 8131.075% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -241486.841% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | -960.373% |
| Generation Bio Co. | -133.3 Million USD | -72.551% |
| Astria Therapeutics, Inc. | -83.03 Million USD | -177.02% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | -167.382% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | -1.133% |
| Invivyd, Inc. | -196.61 Million USD | -16.985% |
| Relay Therapeutics, Inc. | -374.15 Million USD | 38.525% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | -2379.946% |
| Spero Therapeutics, Inc. | 27.15 Million USD | 947.058% |
| Artelo Biosciences, Inc. | -10.28 Million USD | -2136.364% |
| 2seventy bio, Inc. | -206.41 Million USD | -11.429% |
| ADMA Biologics, Inc. | 5.12 Million USD | 4592.383% |
| Clene Inc. | -43.24 Million USD | -431.926% |
| Capricor Therapeutics, Inc. | -23 Million USD | -899.653% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | -374.472% |
| GeoVax Labs, Inc. | -26.66 Million USD | -762.469% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | 23.219% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | -526.229% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | 1075.735% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | 4784.278% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | -608.115% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | -45.205% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 66.388% |
| Evaxion Biotech A/S | -21.4 Million USD | -974.662% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | -246.322% |
| Verve Therapeutics, Inc. | -217.66 Million USD | -5.67% |
| Trevena, Inc. | -35.28 Million USD | -551.808% |
| Surrozen, Inc. | -41.13 Million USD | -459.213% |
| Tyra Biosciences, Inc. | -79.59 Million USD | -188.986% |
| Cingulate Inc. | -22.95 Million USD | -902.134% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | -2982.831% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -516.93% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | -2696.008% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | -124.913% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | -239.113% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | -294.042% |
| Clearmind Medicine Inc. | -8.71 Million USD | -2540.557% |
| Kronos Bio, Inc. | -121.83 Million USD | -88.796% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | -209.394% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -9321.18% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -128.123% |
| Statera Biopharma, Inc. | 38.93 Million USD | 690.755% |
| ImmunityBio, Inc. | -436.18 Million USD | 47.267% |
| Korro Bio, Inc. | -80.9 Million USD | -184.3% |
| Kineta, Inc. | -15.71 Million USD | -1363.727% |
| BioVie Inc. | -31.95 Million USD | -619.901% |
| Codexis, Inc. | -49.28 Million USD | -366.713% |
| Celularity Inc. | -183.94 Million USD | -25.042% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | -3.837% |
| Celcuity Inc. | -58.3 Million USD | -294.461% |
| Virax Biolabs Group Limited | -6.6 Million USD | -3380.178% |
| Cibus, Inc. | -314.58 Million USD | 26.885% |
| Eledon Pharmaceuticals, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | -581.855% |
| IN8bio, Inc. | -28.5 Million USD | -706.939% |
| Kodiak Sciences Inc. | -259.02 Million USD | 11.201% |
| Annexon, Inc. | -141.57 Million USD | -62.465% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | -104.274% |
| Assembly Biosciences, Inc. | -64.19 Million USD | -258.293% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | -722.787% |
| Eyenovia, Inc. | -24.1 Million USD | -854.159% |
| Puma Biotechnology, Inc. | 44.78 Million USD | 613.599% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -70890.741% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | -211.65% |
| Arcellx, Inc. | -64.14 Million USD | -258.578% |
| Cardiff Oncology, Inc. | -45.01 Million USD | -410.974% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | -86.279% |
| Regulus Therapeutics Inc. | -30.88 Million USD | -644.803% |
| Moolec Science SA | -52.07 Million USD | -341.685% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | -345.704% |
| Geron Corporation | -174.78 Million USD | -31.598% |
| LAVA Therapeutics N.V. | -40.41 Million USD | -469.092% |
| Royalty Pharma plc | 1.88 Billion USD | 112.187% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | -92.327% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | -2366.793% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | -1008.976% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | -38.493% |
| Humacyte, Inc. | -96.45 Million USD | -138.456% |
| Structure Therapeutics Inc. | -102.45 Million USD | -124.49% |
| 89bio, Inc. | -134.46 Million USD | -71.058% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | -191.613% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | 5776.456% |
| Genelux Corporation | -24.16 Million USD | -851.831% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | -580.503% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | -40.71% |
| Notable Labs, Ltd. | -14.4 Million USD | -1497.292% |
| Liquidia Corporation | -70.05 Million USD | -228.346% |
| Mustang Bio, Inc. | -48.06 Million USD | -378.559% |
| Immunovant, Inc. | -269.97 Million USD | 14.804% |
| Quantum-Si incorporated | -91.8 Million USD | -150.545% |
| Arbutus Biopharma Corporation | -70.98 Million USD | -224.022% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | -1091.268% |
| Vera Therapeutics, Inc. | -102.01 Million USD | -125.473% |
| Acasti Pharma Inc. | -11.3 Million USD | -1935.307% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | -933.602% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | -1400.303% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | -9.262% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | -5286.218% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | -1348.426% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | -699.312% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | -521.145% |
| PepGen Inc. | -83.58 Million USD | -175.191% |
| Moleculin Biotech, Inc. | -29.5 Million USD | -679.589% |
| United Therapeutics Corporation | 1.38 Billion USD | 116.586% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | -904.542% |
| Solid Biosciences Inc. | -93.43 Million USD | -146.174% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | -4720.258% |
| Immuneering Corporation | -58.06 Million USD | -296.154% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 7172223.48% |
| Silo Pharma, Inc. | -3.62 Million USD | -6242.979% |
| Belite Bio, Inc | -31.52 Million USD | -629.519% |
| XOMA Corporation | -39.36 Million USD | -484.345% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | -241.023% |
| Bionomics Limited | -9.83 Million USD | -2238.214% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | -173.87% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | -564.654% |
| uniQure N.V. | -253.1 Million USD | 9.123% |
| Cassava Sciences, Inc. | -95.68 Million USD | -140.377% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -3046.469% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | -77.608% |
| Forte Biosciences, Inc. | -32.47 Million USD | -608.224% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | -2757.099% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | -715.089% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -70890.741% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | -1964.536% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | -1346.513% |
| Altimmune, Inc. | -87.93 Million USD | -161.568% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -149.796% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | -564.654% |
| Compugen Ltd. | -12.51 Million USD | -1737.728% |
| Peak Bio, Inc. | -1356.23 USD | -16959412.767% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | -373.291% |
| Benitec Biopharma Inc. | -22.49 Million USD | -922.721% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 5.073% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | -705.837% |
| Zura Bio Limited | -60.56 Million USD | -279.786% |
| PolyPid Ltd. | -20.26 Million USD | -1035.123% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | -1373.195% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | -705.837% |
| Instil Bio, Inc. | -146.12 Million USD | -57.41% |
| argenx SE | -216.02 Million USD | -6.475% |
| Immunome, Inc. | -28.27 Million USD | -713.59% |
| Compass Therapeutics, Inc. | -48.47 Million USD | -374.512% |
| Verona Pharma plc | -52.46 Million USD | -338.385% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | -142.698% |
| Shattuck Labs, Inc. | -87.61 Million USD | -162.524% |
| CervoMed Inc. | -2.17 Million USD | -10490.393% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | -88.156% |
| Plus Therapeutics, Inc. | -12.69 Million USD | -1712.101% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | -377.457% |
| Moolec Science SA | -52.07 Million USD | -341.685% |
| Enveric Biosciences, Inc. | -17.13 Million USD | -1241.95% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | -76.4% |
| AnaptysBio, Inc. | -143.16 Million USD | -60.662% |
| Design Therapeutics, Inc. | -66.32 Million USD | -246.792% |
| Leap Therapeutics, Inc. | -80.98 Million USD | -184.009% |
| NeurAxis, Inc. | -6.66 Million USD | -3351.274% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | -509.298% |
| Lumos Pharma, Inc. | -36.57 Million USD | -528.958% |
| Achilles Therapeutics plc | -70.44 Million USD | -226.524% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | -142.698% |
| 180 Life Sciences Corp. | -22.13 Million USD | -939.169% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | 4045.793% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -9321.18% |
| Nutriband Inc. | -5.12 Million USD | -4390.824% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | -109.58% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | -314.941% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | -355.015% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | -252.36% |
| MoonLake Immunotherapeutics | -54.1 Million USD | -325.079% |
| Palisade Bio, Inc. | -12.28 Million USD | -1772.893% |
| Tourmaline Bio, Inc. | -45.37 Million USD | -406.898% |
| Beam Therapeutics Inc. | -156.47 Million USD | -46.997% |
| Neurogene Inc. | -52.28 Million USD | -339.907% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | -68.518% |
| AEON Biopharma, Inc. | -48.36 Million USD | -375.611% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | -147.275% |
| Sesen Bio, Inc. | -50.84 Million USD | -352.419% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | -180.733% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | -1762.426% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | 46.188% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | -118.647% |
| Athira Pharma, Inc. | -116.7 Million USD | -97.09% |
| Vaccinex, Inc. | -19.74 Million USD | -1064.726% |
| HCW Biologics Inc. | -23.57 Million USD | -875.608% |
| XOMA Corporation | -39.36 Million USD | -484.345% |
| Nektar Therapeutics | -243.1 Million USD | 5.387% |
| Arvinas, Inc. | -394.8 Million USD | 41.74% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 121988.016% |
| Merus N.V. | -149.2 Million USD | -54.155% |
| Omega Therapeutics, Inc. | -93.49 Million USD | -146.026% |
| Quince Therapeutics, Inc. | -31.26 Million USD | -635.797% |
| Rezolute, Inc. | -68.42 Million USD | -236.159% |
| Clene Inc. | -43.24 Million USD | -431.926% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | -1391.422% |
| BeyondSpring Inc. | -21.54 Million USD | -967.827% |
| Synlogic, Inc. | -55.16 Million USD | -316.979% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | -1803.584% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | -2061.342% |
| Peak Bio, Inc. | -1356.23 USD | -16959412.767% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | -608.486% |
| Krystal Biotech, Inc. | 17.9 Million USD | 1384.685% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | -94.227% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | 32.617% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | -4893.236% |
| MannKind Corporation | 15.12 Million USD | 1620.325% |
| Ikena Oncology, Inc. | -74.39 Million USD | -209.166% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | -1726.491% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | 1231.549% |
| Gossamer Bio, Inc. | -172.15 Million USD | -33.609% |
| CohBar, Inc. | -12.06 Million USD | -1806.304% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | -801.682% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | -666.062% |
| Legend Biotech Corporation | -477.87 Million USD | 51.868% |
| Mural Oncology plc | -192.72 Million USD | -19.349% |
| Biora Therapeutics, Inc. | -114.05 Million USD | -101.668% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -1324.628% |
| Disc Medicine, Inc. | -91.02 Million USD | -152.689% |
| Champions Oncology, Inc. | -5.05 Million USD | -4451.049% |
| REGENXBIO Inc. | -239.46 Million USD | 3.948% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | -2045.979% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -312.53% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | -493.294% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | -103.899% |
| Vaxart, Inc. | -74.72 Million USD | -207.817% |
| PharmaCyte Biotech, Inc. | - USD | Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | -553.284% |
| Cellectis S.A. | -98.09 Million USD | -134.477% |
| Longeveron Inc. | -20.06 Million USD | -1046.61% |
| Repare Therapeutics Inc. | -114.27 Million USD | -101.281% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 47.629% |
| Inozyme Pharma, Inc. | -74.81 Million USD | -207.451% |
| Revolution Medicines, Inc. | -430.58 Million USD | 46.582% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | -3557.338% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | -647.053% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | -208.366% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | 4791.209% |
| Anixa Biosciences, Inc. | -10.96 Million USD | -1997.674% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 104.995% |
| Denali Therapeutics Inc. | -179.97 Million USD | -27.803% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -241486.841% |
| Veru Inc. | -89.97 Million USD | -155.636% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | -755.756% |
| Cingulate Inc. | -22.95 Million USD | -902.134% |
| Passage Bio, Inc. | -98.34 Million USD | -133.89% |
| Context Therapeutics Inc. | -25.06 Million USD | -817.816% |
| Exicure, Inc. | -15.53 Million USD | -1380.211% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | -11.621% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | -522.052% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | -3757.548% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | -36.534% |
| Nuvalent, Inc. | -149.49 Million USD | -53.861% |
| ABVC BioPharma, Inc. | -8.13 Million USD | -2728.311% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | -167.784% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | -662.178% |
| OmniAb, Inc. | -49.73 Million USD | -362.508% |
| Anew Medical, Inc. | -1.3 Million USD | -17581.652% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | -1760.32% |
| Lipocine Inc. | -16.32 Million USD | -1309.145% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | -244.998% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | -209.557% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | -503.175% |
| G1 Therapeutics, Inc. | -39.01 Million USD | -489.558% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | -936.875% |
| Sage Therapeutics, Inc. | -545.07 Million USD | 57.802% |
| Ocugen, Inc. | -64.82 Million USD | -254.806% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | -148.471% |
| Q32 Bio Inc. | -86.5 Million USD | -165.901% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | -1258.835% |
| Alumis Inc. Common Stock | -156.89 Million USD | -46.606% |
| Equillium, Inc. | -12.13 Million USD | -1794.958% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | -293.368% |
| Coya Therapeutics, Inc. | -7.9 Million USD | -2810.285% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | -1119.502% |
| Galera Therapeutics, Inc. | -46.69 Million USD | -392.611% |
| Evelo Biosciences, Inc. | -106.34 Million USD | -116.287% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | -1185.935% |
| Dominari Holdings Inc. | -22.44 Million USD | -925.0% |
| Edesa Biotech, Inc. | -8.19 Million USD | -2708.376% |
| vTv Therapeutics Inc. | -25.41 Million USD | -805.124% |
| Bio-Techne Corporation | 326.66 Million USD | 170.412% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | 40.236% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | 206.295% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | -75.436% |
| Candel Therapeutics, Inc. | -37.43 Million USD | -514.491% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | -52.223% |
| Nkarta, Inc. | -120.48 Million USD | -90.91% |
| BioCardia, Inc. | -11.56 Million USD | -1889.706% |
| Iterum Therapeutics plc | -34.58 Million USD | -565.153% |